{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    9,
    11,
    22,
    32
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_2",
        "affectedSection": "Section 6.7.2, 8.4.5, 9.1.1",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Mandatory treatment discontinuation for subjects developing retinal vasculitis (RV) and/or retinal vascular occlusion (RO)."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_2",
        "affectedSection": "Section 4.5 - Risks and benefits",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added information regarding gender imbalance observed in intraocular inflammation (IOI) following brolucizumab treatment."
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_2",
        "affectedSection": "Section 8.4.3 - Pregnancy",
        "impactLevel": "Administrative",
        "instanceType": "StudyAmendmentImpact",
        "description": "Standardization of pregnancy testing requirements across both study arms."
      },
      {
        "id": "impact_4",
        "amendmentId": "amend_1",
        "affectedSection": "Section 6.7.2 - Instructions for administering study treatment",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Prohibition of IVT injection if any sign of intraocular inflammation is present."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_2",
        "reasonText": "Implementation of Urgent Safety Measures (USM) following identification of causal immune-mediated mechanism for RV and RO.",
        "category": "Safety",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_2",
        "reasonText": "Recommendations on time windows for COVID-19 vaccine or vitrectomy.",
        "category": "Operational",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "amend_1",
        "reasonText": "Post-marketing reports of retinal vasculitis and/or retinal vascular occlusion in nAMD treatment.",
        "category": "Safety",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_4",
        "amendmentId": "amend_1",
        "reasonText": "Modifications due to the COVID-19 pandemic.",
        "category": "Operational",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_2",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "6.7.2",
        "beforeText": "Not specified",
        "afterText": "Requirement of treatment discontinuation was added if subject developed RV and/or RO, in both arms.",
        "summary": "Added mandatory discontinuation rule for RV/RO events."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_2",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "8.4.3",
        "beforeText": "Inconsistent pregnancy testing requirements",
        "afterText": "Requirement to apply the same pregnancy testing in both arms, throughout the study.",
        "summary": "Corrected inconsistency in pregnancy testing protocols between arms."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_1",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "6.7.2",
        "beforeText": "Standard injection guidance",
        "afterText": "If any sign of intraocular inflammation is present, an IVT injection must not be performed.",
        "summary": "Emphasized withholding treatment in the presence of IOI."
      },
      {
        "id": "change_4",
        "amendmentId": "amend_1",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "Title Page",
        "beforeText": "CONDOR",
        "afterText": "Added approved study bird nickname.",
        "summary": "Administrative update to study branding."
      }
    ],
    "summary": {
      "impactCount": 4,
      "reasonCount": 4,
      "changeCount": 4
    }
  }
}